Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end ...

A significant development emerged on November 13 when Pfizer announced it had sold 54.7% of its stake in BioNTech, retaining only $163.5 million worth of shares. This move marks a substantial shift in ...

BioNTech formally launched its public takeover bid on October 22, 2025, offering CureVac shareholders approximately $5.46 per share in BioNTech American Depositary Shares. The exchange ratio includes ...

SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...

Get the latest New Zealand national news now. Discover breaking news and in-depth coverage with videos and photos.

The German biopharmaceutical company BioNTech finds itself at a critical juncture following a significant divestment by its ...

Arturo Bris, IMD professor in geopolitics and business, examines Europe’s often-overlooked innovation engine, unpacking why ...

At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...

Pfizer has sold a significant portion of its stake in German drugmaker BioNTech SE, a more than five years after the two ...

The strategic partnership that yielded one of history's most successful vaccines reached a turning point this week. Pfizer ...

BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.